In addition to further advances in the ICI-VEGF, ICI-Chemotherapy, and ICI plus BRAF inhibitor, there are several other intriguing combinations based on combinations of immune modulators like CAR-T therapies69 and immune activators45 and ICI-ICI combinations.23,24 The combination of a next-generation anti-CTLA4 inhibitor, botensilimab, and balstilimab (anti-PD-1) was recently evaluated in 41 patients with heavily pretreated (median of 4 prior treatments) patients with MSS CRC. This evidence concerns the gene CTLA4 and colorectal carcinoma.